Maj Invest Holding A S Sells 78,471 Shares of Zoetis Inc. $ZTS

Maj Invest Holding A S reduced its position in Zoetis Inc. (NYSE:ZTS) by 11.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 596,697 shares of the company’s stock after selling 78,471 shares during the quarter. Zoetis accounts for approximately 1.9% of Maj Invest Holding A S’s holdings, making the stock its 18th biggest holding. Maj Invest Holding A S owned approximately 0.14% of Zoetis worth $42,877,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. J. Stern & Co. LLP grew its stake in shares of Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. Norges Bank purchased a new stake in shares of Zoetis in the fourth quarter worth approximately $734,425,000. Vanguard Group Inc. lifted its stake in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. bought a new stake in shares of Zoetis during the 1st quarter worth approximately $286,660,000. Finally, Van ECK Associates Corp boosted its holdings in Zoetis by 269.0% during the 4th quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock valued at $300,340,000 after acquiring an additional 1,740,113 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 6.1%

ZTS opened at $72.53 on Friday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The stock’s fifty day moving average is $76.66 and its two-hundred day moving average is $100.75. The company has a market capitalization of $30.41 billion, a P/E ratio of 11.95, a PEG ratio of 1.26 and a beta of 0.74. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $160.48.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 70.95% and a net margin of 27.49%.The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the prior year, the business earned $1.76 EPS. The business’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts forecast that Zoetis Inc. will post 6.43 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio is presently 34.93%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Stifel Nicolaus cut their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Barclays lowered their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Morgan Stanley set a $85.00 price objective on shares of Zoetis in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $115.50.

Insider Activity

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by corporate insiders.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.